| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*
Rheumatology, Immunology, and Genetics Program, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan; and
Division of Allergology and Rheumatology, Department of Medicine, University of Tokyo, Tokyo, Japan;
Department of Immunology, Juntendo University School of Medicine, Juntendo, Japan; and
§
Department of Allergy and Immunology, National Children’s Medical Research Center, Tokyo, Japan
To determine whether antilymphocyte Abs to T cell costimulatory molecules are generated in patients with autoimmune diseases and, if they exist, to clarify the mechanism of their production and pathological roles, we investigated the presence of autoantibodies to CTLA-4 (CD152), CD28, B7-1 (CD80), and B7-2 (CD86) in serum samples obtained from patients with various autoimmune diseases and from normal subjects using recombinant fusion proteins. In ELISAs, anti-CD28, anti-B7-1, and anti-B7-2 Abs were rarely seen, whereas anti-CTLA-4 Abs were detected in 8.2% of the patients with systemic lupus erythematosus, 18.8% of those with rheumatoid arthritis, 3.1% of those with systemic sclerosis, 31.8% of those with Behçet’s disease, 13.3% of those with Sjögren’s syndrome, and 0% of healthy donors. This reactivity was confirmed by immunoblotting. More importantly, the purified anti-CTLA-4 Abs reacted with CTLA-4 expressed on P815 cells by flow cytometry. In addition, we found at least three epitopes on the CTLA-4 molecule. Furthermore, among the patients with Behçet’s disease, uveitis was seen significantly less frequently in the anti-CTLA-4 Ab-positive patients. Taken collectively, these data indicate that anti-CTLA-4 autoantibodies are generated in systemic autoimmune diseases by an Ag-driven mechanism and may modulate the immune response in vivo by binding to CTLA-4 on T cells.
This article has been cited by other articles:
|
|
 |
|
  W. Stohl, N. Jacob, W. J. Quinn III, M. P. Cancro, H. Gao, C. Putterman, X. Gao, L. Pricop, and M. N. Koss Global T Cell Dysregulation in Non-Autoimmune-Prone Mice Promotes Rapid Development of BAFF-Independent, Systemic Lupus Erythematosus-Like Autoimmunity J. Immunol., July 1, 2008; 181(1): 833 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Wan, H. Nie, A. Liu, G. Feng, D. He, R. Xu, Q. Zhang, C. Dong, and J. Z. Zhang Aberrant Regulation of Synovial T Cell Activation by Soluble Costimulatory Molecules in Rheumatoid Arthritis J. Immunol., December 15, 2006; 177(12): 8844 - 8850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xiang, T. Sekine, H. Nakamura, S. Imajoh-Ohmi, H. Fukuda, K. Yudoh, K. Masuko-Hongo, K. Nishioka, and T. Kato Fibulin-4 is a target of autoimmunity predominantly in patients with osteoarthritis. J. Immunol., March 1, 2006; 176(5): 3196 - 3204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z Yao, H Nakamura, K Masuko-Hongo, M Suzuki-Kurokawa, K Nishioka, and T Kato Characterisation of cartilage intermediate layer protein (CILP)-induced arthropathy in mice Ann Rheum Dis, March 1, 2004; 63(3): 252 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zheng and M. Monestier Inhibitory Signal Override Increases Susceptibility to Mercury-Induced Autoimmunity J. Immunol., August 1, 2003; 171(3): 1596 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Direskeneli Behcet's disease: infectious aetiology, new autoantigens, and HLA-B51 Ann Rheum Dis, November 1, 2001; 60(11): 996 - 1002. [Full Text] [PDF]
|
|
|
|
|
|
X. Yu, T. Matsui, M. Otsuka, T. Sekine, K. Yamamoto, K. Nishioka, and T. Kato Anti-CD69 Autoantibodies Cross-React with Low Density Lipoprotein Receptor-Related Protein 2 in Systemic Autoimmune Diseases J. Immunol., January 15, 2001; 166(2): 1360 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Sekine, K Masuko-Hongo, T Matsui, H Asahara, M Takigawa, K Nishioka, and T Kato Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis Ann Rheum Dis, January 1, 2001; 60(1): 49 - 54. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. A. Hurwitz, T. J. Sullivan, R. A. Sobel, and J. P. Allison Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice PNAS, March 5, 2002; 99(5): 3013 - 3017. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
